Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Characterization of an intracellular ATP assay for evaluating the viability of live attenuated mycobacterial vaccine preparations.

Kolibab K, Derrick SC, Jacobs WR, Morris SL.

J Microbiol Methods. 2012 Sep;90(3):245-9. doi: 10.1016/j.mimet.2012.05.015. Epub 2012 May 28.

PMID:
22652432
2.

Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains.

Ho MM, Markey K, Rigsby P, Hockley J, Corbel MJ.

Vaccine. 2011 Jan 10;29(3):512-8. doi: 10.1016/j.vaccine.2010.10.066. Epub 2010 Nov 4.

PMID:
21055496
3.

The use of mutant mycobacteria as new vaccines to prevent tuberculosis.

Hernàndez Pando R, Aguilar LD, Infante E, Cataldi A, Bigi F, Martin C, Gicquel B.

Tuberculosis (Edinb). 2006 May-Jul;86(3-4):203-10. Epub 2006 Mar 20. Review.

PMID:
16542875
4.

Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine.

Ho MM, Markey K, Rigsby P, Jensen SE, Gairola S, Seki M, Castello-Branco LR, López-Vidal Y, Knezevic I, Corbel MJ.

Vaccine. 2008 Aug 26;26(36):4754-7. doi: 10.1016/j.vaccine.2008.06.026. Epub 2008 Jun 27.

PMID:
18586063
5.

Firefly luciferase assay of adenosine triphosphate as a tool of quantitation of the viability of BCG vaccines.

Askgaard DS, Gottschau A, Knudsen K, Bennedsen J.

Biologicals. 1995 Mar;23(1):55-60.

PMID:
7619437
6.

The second Geneva Consensus: Recommendations for novel live TB vaccines.

Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J, Dobbelaer R, Grode L, Liu MA, Fruth U, Lambert PH.

Vaccine. 2010 Mar 8;28(11):2259-70. doi: 10.1016/j.vaccine.2009.12.083. Epub 2010 Jan 20. Review.

PMID:
20074686
7.

Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine.

Jensen SE, Hubrechts P, Klein BM, Hasløv KR.

Biologicals. 2008 Sep;36(5):308-14. doi: 10.1016/j.biologicals.2008.05.001. Epub 2008 Jul 9.

PMID:
18614376
8.

Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant.

Senaratne RH, Mougous JD, Reader JR, Williams SJ, Zhang T, Bertozzi CR, Riley LW.

J Med Microbiol. 2007 Apr;56(Pt 4):454-8.

PMID:
17374883
9.
10.

The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.

de Lisle GW, Wards BJ, Buddle BM, Collins DM.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):73-9. Epub 2004 Dec 28.

PMID:
15687030
11.

Development of live recombinant vaccine candidates against tuberculosis.

Hess J, Kaufmann SH.

Scand J Infect Dis. 2001;33(10):723-4.

PMID:
11728033
12.

Newly attenuated Mycobacterium bovis mutants as vaccines against bovine tuberculosis, particularly for possums.

Collins DM, Buddle BM, Kawakami RP, Hotter G, Mildenhall N, Mouat P, Murney R, Ataera H, Price-Carter M, Bruere P, Wards BJ, de Lisle GW.

Vet Microbiol. 2011 Jul 5;151(1-2):99-103. doi: 10.1016/j.vetmic.2011.02.031. Epub 2011 Feb 24.

PMID:
21420259
13.

A new attenuated Mycobacterium bovis vaccine protects brushtail possums (Trichosurus vulpecula) against experimental tuberculosis infection.

Collins DM, de Lisle GW, Aldwell FE, Buddle BM.

Vaccine. 2007 Jun 11;25(24):4659-64. Epub 2007 Apr 26.

PMID:
17498852
14.

Influence of advanced age on Mycobacterium bovis BCG vaccination in guinea pigs aerogenically infected with Mycobacterium tuberculosis.

Komine-Aizawa S, Yamazaki T, Yamazaki T, Hattori S, Miyamoto Y, Yamamoto N, Haga S, Sugitani M, Honda M, Hayakawa S, Yamamoto S.

Clin Vaccine Immunol. 2010 Oct;17(10):1500-6. doi: 10.1128/CVI.00190-10. Epub 2010 Aug 4.

15.

Cultivation of Mycobacterium bovis BCG in bioreactors.

Dietrich G, Mollenkopf HJ, Weber H, Knapp B, Diehl KD, Hess J, Blackkolb F, Bröker M, Kaufmann SH, Hundt E.

J Biotechnol. 2002 Jul 3;96(3):259-70.

PMID:
12044554
16.

Vaccine and skin testing properties of two avirulent Mycobacterium bovis mutants with and without an additional esat-6 mutation.

Collins DM, Kawakami RP, Wards BJ, Campbell S, de Lisle GW.

Tuberculosis (Edinb). 2003;83(6):361-6.

PMID:
14623166
17.

Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains.

Gheorghiu M, Lagrange PH.

Ann Immunol (Paris). 1983 Jan-Feb;134C(1):125-47.

PMID:
6344747
18.

Recombinant Mycobacterium bovis BCG.

Bastos RG, Borsuk S, Seixas FK, Dellagostin OA.

Vaccine. 2009 Nov 5;27(47):6495-503. doi: 10.1016/j.vaccine.2009.08.044. Epub 2009 Aug 29. Review.

PMID:
19720367
19.

Improving vaccines against tuberculosis.

Britton WJ, Palendira U.

Immunol Cell Biol. 2003 Feb;81(1):34-45.

20.

New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development.

Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, Mayner RE, Thole J, Walker KB, Liu M, Lambert PH; AERAS Global TB Vaccine Foundation.; World Health Organization..

Vaccine. 2005 May 31;23(29):3753-61. Epub 2005 Mar 24. Review.

PMID:
15893612

Supplemental Content

Support Center